Scroll to top

Scroll to top

News Releases

Home
Investors
News Releases

News Releases

Month Year

Month Year

Investor Alerts

March 20, 2024

Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States
March 7, 2024

Immunic to Participate in Investor and Scientific Conferences in March
February 29, 2024

Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024
February 22, 2024

Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update
February 15, 2024

Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2023, and Provide Corporate Update
February 1, 2024

Immunic to Participate in Investor and Scientific Conferences in February
January 5, 2024

Immunic Highlights 2023 Accomplishments and Upcoming Milestones
January 5, 2024

Immunic, Inc. Announces Private Placement of up to $240 Million
November 21, 2023

Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dosing Regimens in Multiple Sclerosis
November 14, 2023

Immunic, Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Show per page